The stock price of PTC Therapeutics Inc (NASDAQ: PTCT) has dropped by -6.82 compared to previous close of 42.38. Despite this, the company has seen a fall of -10.82% in its stock price over the last five trading days. reuters.com reported 2024-11-13 that The U.S. Food and Drug Administration approved PTC Therapeutics’ gene therapy that is administered directly in the brain to treat a potential fatal enzyme deficiency disorder, the company said on Wednesday.
Is It Worth Investing in PTC Therapeutics Inc (NASDAQ: PTCT) Right Now?
The stock has a 36-month beta value of 0.62. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 1 as “overweight,” 6 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PTCT is 74.59M, and at present, short sellers hold a 6.55% of that float. On November 15, 2024, the average trading volume of PTCT was 690.77K shares.
PTCT’s Market Performance
PTCT stock saw an increase of -10.82% in the past week, with a monthly gain of 6.70% and a quarterly increase of 14.60%. The volatility ratio for the week is 5.18%, and the volatility levels for the last 30 days are 4.99% for PTC Therapeutics Inc (PTCT). The simple moving average for the last 20 days is -5.24% for PTCT’s stock, with a simple moving average of 18.91% for the last 200 days.
Analysts’ Opinion of PTCT
Robert W. Baird, on the other hand, stated in their research note that they expect to see PTCT reach a price target of $44. The rating they have provided for PTCT stocks is “Outperform” according to the report published on September 04th, 2024.
UBS gave a rating of “Buy” to PTCT, setting the target price at $47 in the report published on August 26th of the current year.
PTCT Trading at 2.82% from the 50-Day Moving Average
After a stumble in the market that brought PTCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.94% of loss for the given period.
Volatility was left at 4.99%, however, over the last 30 days, the volatility rate increased by 5.18%, as shares surge +0.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.38% upper at present.
During the last 5 trading sessions, PTCT fell by -11.40%, which changed the moving average for the period of 200-days by +50.71% in comparison to the 20-day moving average, which settled at $41.66. In addition, PTC Therapeutics Inc saw 43.29% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PTCT starting from Gravier Pierre, who sale 2,269 shares at the price of $34.02 back on Jul 16 ’24. After this action, Gravier Pierre now owns 53,531 shares of PTC Therapeutics Inc, valued at $77,200 using the latest closing price.
ZELDIS JEROME B, the Director of PTC Therapeutics Inc, sale 20,000 shares at $38.24 during a trade that took place back on May 22 ’24, which means that ZELDIS JEROME B is holding 14,500 shares at $764,800 based on the most recent closing price.
Stock Fundamentals for PTCT
Current profitability levels for the company are sitting at:
- -0.14 for the present operating margin
- 0.78 for the gross margin
The net margin for PTC Therapeutics Inc stands at -0.5. The total capital return value is set at -0.11.
Based on PTC Therapeutics Inc (PTCT), the company’s capital structure generated -0.37 points at debt to capital in total, while cash flow to debt ratio is standing at -0.62. The debt to equity ratio resting at -0.27. The interest coverage ratio of the stock is -0.77.
Currently, EBITDA for the company is -330.34 million with net debt to EBITDA at 1.19. When we switch over and look at the enterprise to sales, we see a ratio of 3.28. The receivables turnover for the company is 4.5for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.10.
Conclusion
To sum up, PTC Therapeutics Inc (PTCT) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
